| abstract |
A bispecific antibody for use in the treatment or prevention of an acute thrombotic disorder in a patient, wherein said antibody comprises: a. a first target domain that specifically binds to thrombin-activatable fibrinolysis inhibitor (TAFI) and comprises complementarity determining regions (CDRs) represented by the amino acid sequences SEQ ID NO: 1 of CDR1H, SEQ ID NO: 2 of CDR2H, SEQ ID NO: 3 of CDR3H, SEQ ID NO: 4 of CDR1L, SEQ ID NO: 5 of CDR2L and SEQ ID NO: 6 of CDR3L; and b. a second target domain that specifically binds plasminogen activator inhibitor-1 (PAI-1) and comprises complementarity determining regions (CDRs) represented by CDR1H SEQ ID NO: 7, CDR2H SEQ ID NO: 8, SEQ ID CDR3H SEQ ID NO: 9, CDR1L SEQ ID NO: 10, CDR2L SEQ ID NO: 11 and CDR3L SEQ ID NO: 12. |